EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Supplementation of Dihomo-γ-Linolenic Acid for Pollen-Induced Allergic Symptoms in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Trial

Kaori Yokoi, Kenichi Yanagimoto, Kohsuke Hayamizu

Nutrients · 2023

DOI: 10.3390/nu15153465 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2023. Verfasst von Kaori Yokoi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Food Function R&D Center, Nissui Corporation, Tokyo 192-0919, Japan. Hauptthemen laut MEDLINE: Pollen, Dietary Supplements, 8,11,14-Eicosatrienoic Acid, Rhinitis, Allergic, Seasonal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nissui Corporaion (The company name was changed from Nippon Suisan Kaisha to Nissui Corporation in December 2022.), Nissui Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dihomo-γ-linolenic acid (DGLA) is an n-6 polyunsaturated fatty acid that has been shown to have anti-inflammatory and anti-allergic effects in mice and cell study. To date, however, no human intervention study has examined the effects of DGLA. Therefore, we investigated the effects of DGLA on pollen-induced allergic symptoms in healthy adults. We performed a randomized, double-blind, placebo-controlled, parallel-group study comprising healthy Japanese men and women. Each subject received four 250 mg capsules providing 314 mg DGLA/day (DGLA group, n = 18) or olive oil (placebo group, n = 15) for 15 weeks. The primary outcomes, classification of the severity of allergic rhinitis symptoms (CSARS), and the Japanese Rhino-conjunctivitis Quality of Life Questionnaire (JRQLQ) served as symptom scores during the pollen season. In the DGLA group, the cedar pollen associated symptoms of sneezing and a blocked nose in the CSARS were significantly lower than those in the placebo group (p < 0.05, p < 0.01, respectively). Significant trends were observed the symptoms of runny nose in the CSARS and total symptom score (TSS) in the JRQLQ for cedar pollen (p < 0.1). To our knowledge, this is the first study to report the effects of DGLA in humans, and the results suggest that DGLA is effective in reducing allergic symptoms caused by pollen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PollenDietary Supplements8,11,14-Eicosatrienoic AcidRhinitis, Allergic, SeasonalHumansFemaleDouble-Blind MethodMaleAdultYoung AdultQuality of LifeMiddle AgedHealthy VolunteersCryptomeria

Stichwörter der Autor:innen

allergydihomo-γ-linolenic acidhealthy subjectunsaturated fatty acid

Substanzen

8,11,14-Eicosatrienoic Acid

Autor:innen und Institutionen

  • Food Function R&D Center, Nissui Corporation, Tokyo 192-0919, Japan.
  • Laboratory of Food Chemistry, Yokohama University of Pharmacy, Yokohama 245-0066, Japan.

Förderung

  • Nissui Corporaion (The company name was changed from Nippon Suisan Kaisha to Nissui Corporation in December 2022.)
  • Nissui Corporation

Zitieren

APA

Yokoi, K., Yanagimoto, K., & Hayamizu, K. (2023). Supplementation of Dihomo-γ-Linolenic Acid for Pollen-Induced Allergic Symptoms in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Trial. Nutrients. https://doi.org/10.3390/nu15153465

Vancouver

Yokoi K, Yanagimoto K, Hayamizu K. Supplementation of Dihomo-γ-Linolenic Acid for Pollen-Induced Allergic Symptoms in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Trial. Nutrients. 2023. doi:10.3390/nu15153465

BibTeX
@article{Yokoi2023,
  author = {Yokoi, Kaori and Yanagimoto, Kenichi and Hayamizu, Kohsuke},
  title = {Supplementation of Dihomo-γ-Linolenic Acid for Pollen-Induced Allergic Symptoms in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Trial},
  journal = {Nutrients},
  year = {2023},
  doi = {10.3390/nu15153465}
}
Kostenlos starten →